Biotechnology News

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the...

MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today...

Pivotal SkinTE® data in non-healing Wagner Grade 1 diabetic foot ulcers to be presented by Study Chair Robert S. Kirsner, MD, PhD, on October 16 SALT LAKE CITY, Sept. 29, 2026 (GLOBE NEWSWIRE) --...

Cascade Prodrug Inc. Appoints Kenneth Mandell, M.D., Ph.D. to Board of Directors

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA,...

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) – – To-date, all patients achieving MRD-negativity reached CR...

Company announcement no. 37 - 2629 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical...

Kither Biotech announces that it has dosed the first patients in its Phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe COPD.

Breye Therapeutics raises €67.5 million in over-subscribed Series A financing round from new and existing investors